Development of Clinical Trials Outcome Instruments for Acne Vulgaris

寻常痤疮临床试验结果仪器的开发

基本信息

项目摘要

DESCRIPTION (provided by applicant): Acne is the most common skin condition that affects ~ 85% of the adolescent population in the United States and accounts for expenditure of billions of health care dollars annually. In this era of change in the economy and change in health care practice patterns, there is an increasing need for practitioners to make evidence-based decisions regarding acne treatment. Although large numbers of clinical trials have been conducted for the hundreds of available acne medications, there is very little data available by which one treatment can be compared to another. Resources to conduct large clinical trials to compare acne therapies are limited. Moving forward, it is more likely that comparative effectiveness research in the area of acne will rely upon secondary analysis of clinical trial data sets. Progress in this area has been greatly hampered by the lack of standardized outcomes measures in acne clinical trials that allows comparison across studies. Following the model of the OMERACT group in rheumatology, an international multi-stakeholder group of experts in evaluation of acne, care of acne patients with diverse skin phototypes, social psychology, analysis of data from acne trials, regulatory affairs, measurement of patient reported outcomes and patient representatives have been assembled and named Acne Core Outcomes Research Network (ACORN). A scientific advisory board of experts will be appointed to provide direction to ACORN initiatives. The approach will be to accomplish a series of short-term objectives that will serve as resources in acne evaluation while pursing the long-term goal to develop a "tool box" of validated outcome measures for use in acne clinical trials. At present, acne lesion counts and investigator global assessment of acne severity are the 2 major outcomes measured in regulatory trials. In addition, there is a lack of patient-reported outcomes measures of truncal acne that affects ~ half of all acne patients. Short-term objectives include: 1). Development of a web- based standardized instrument for lesion counting in acne (SILCA) to improve the variability associated with acne lesion counting; 2). Development of a comprehensive instrument to assess the impact of truncal acne on patient's quality of life (CompAQ); and 3). Generation of pilot data on a series of 4 novel technologies to assess acne and/or train acne evaluators. Progress towards our long-term objective will include, reaching consensus on outcome domains and desired features of outcome measures, completion of systematic reviews of acne outcome measures of acne severity and its impact, assessment of reliability and feasibility of select global assessment scales and preliminary development of a new or revised global severity scale(s). A team-based strategy will be used to simultaneously pursue the project aims. Each team has designated primary responsibility for portions of the project. Teams are based in the US (Drs. Thiboutot/Chren); the UK (Drs.Layton/Eady) and Canada (Drs.Tan/Wolfe). Global communication strategies will supplement face-to-face meetings and Six Sigma principles of project management will be employed.
描述(申请人提供):痤疮是最常见的皮肤疾病,影响到美国约85%的青少年人口,每年花费数十亿美元的医疗保健费用。在这个经济变化和卫生保健实践模式变化的时代,从业者越来越需要对痤疮治疗做出基于证据的决定。尽管已经对数百种可用的痤疮药物进行了大量的临床试验,但可以用来比较一种治疗方法和另一种治疗方法的数据很少。用于进行大型临床试验以比较痤疮疗法的资源有限。展望未来,痤疮领域的比较有效性研究更有可能依赖于对临床试验数据的二次分析 布景。由于痤疮临床试验中缺乏标准化的结果衡量标准,无法进行跨研究比较,这大大阻碍了这一领域的进展。遵循OMERACT风湿病学小组的模式,一个由评估痤疮、护理不同皮肤类型的痤疮患者、社会心理学、痤疮试验数据分析、法规事务、患者报告结果测量和患者代表组成的国际多方利益相关者专家小组已经组建,并命名为痤疮核心结果研究网络(ACORN)。将任命一个由专家组成的科学咨询委员会,为ACORN倡议提供指导。该方法将实现一系列短期目标,作为痤疮评估的资源,同时追求长期目标,开发用于痤疮临床试验的有效结果测量的“工具箱”。目前,痤疮皮损计数和研究人员对痤疮严重程度的全球评估是监管试验中衡量的两个主要结果。此外,缺乏患者报告的躯干预后衡量标准。 粉刺影响了大约一半的粉刺患者。短期目标包括:1)。开发基于网络的痤疮皮损计数标准化仪器(SILCA),以改善与痤疮皮损计数相关的变异性;2)。开发一种综合工具来评估躯干痤疮对患者生活质量的影响(COMPAQ);以及3)。生成一系列4项新技术的试点数据,以评估痤疮和/或培训痤疮评估员。朝着我们的长期目标取得的进展将包括:就结果领域和结果措施的期望特征达成共识,完成对痤疮严重程度及其影响的结果措施的系统审查,评估选定的全球评估量表的可靠性和可行性,以及初步制定新的或修订的全球严重程度量表(S)。以团队为基础的战略将被用于同时追求项目目标。每个团队都指定了项目部分的主要责任。团队的总部设在美国(ThiBoutot/Chren博士)、英国(Layton/Eady博士)和加拿大(Tan/Wolfe博士)。全球沟通战略将补充面对面的会议,并将采用项目管理的六西格玛原则。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Assessing effectiveness in acne clinical trials: steps towards a core outcome measure set.
评估痤疮临床试验的有效性:制定核心结果衡量标准的步骤。
  • DOI:
    10.1111/bjd.18011
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Thiboutot,DM;Layton,AM;Chren,M-M;Eady,EA;Tan,J
  • 通讯作者:
    Tan,J
Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review.
识别痤疮的影响以及使用调查问卷来检测这些影响:系统文献综述。
  • DOI:
    10.1007/s40257-020-00564-6
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Smith,Hayley;Layton,AlisonM;Thiboutot,Diane;Smith,Abbey;Whitehouse,Heather;Ghumra,Waseem;Verma,Meenakshi;Tan,Jerry;Jones,Georgina;Gilliland,Kathryn;Patel,Megha;Otchere,Elaine;Eady,Anne
  • 通讯作者:
    Eady,Anne
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DIANE M. THIBOUTOT其他文献

DIANE M. THIBOUTOT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DIANE M. THIBOUTOT', 18)}}的其他基金

Penn State Institutional Career Development Core
宾夕法尼亚州立大学机构职业发展核心
  • 批准号:
    9322061
  • 财政年份:
    2016
  • 资助金额:
    $ 20.01万
  • 项目类别:
Penn State Institutional Career Development Core
宾夕法尼亚州立大学机构职业发展核心
  • 批准号:
    9352887
  • 财政年份:
    2016
  • 资助金额:
    $ 20.01万
  • 项目类别:
Development of Clinical Trials Outcome Instruments for Acne Vulgaris
寻常痤疮临床试验结果仪器的开发
  • 批准号:
    8701239
  • 财政年份:
    2013
  • 资助金额:
    $ 20.01万
  • 项目类别:
Development of Clinical Trials Outcome Instruments for Acne Vulgaris
寻常痤疮临床试验结果仪器的开发
  • 批准号:
    8580866
  • 财政年份:
    2013
  • 资助金额:
    $ 20.01万
  • 项目类别:
SECRETION OF NGAL ON THE SKIN OF PATIENTS TREATED WITH ISOTRETINOIN
异维A酸治疗患者皮肤上 NGAL 的分泌
  • 批准号:
    7625802
  • 财政年份:
    2007
  • 资助金额:
    $ 20.01万
  • 项目类别:
ANALYSIS OF GENE EXPRESSION IN THE SKIN OF PATIENTS TREATED WITH ISOTRETINON
异维A酮治疗患者皮肤基因表达分析
  • 批准号:
    7378457
  • 财政年份:
    2006
  • 资助金额:
    $ 20.01万
  • 项目类别:
ASSESS SEBUM PRODUCTION IN SUBJECTS TREATED WITH FIBRATES OR THIAZOLIDINEDIONES
评估接受贝特类药物或噻唑烷二酮治疗的受试者的皮脂产生情况
  • 批准号:
    7203480
  • 财政年份:
    2005
  • 资助金额:
    $ 20.01万
  • 项目类别:
ANALYSIS OF GENE EXPRESSION IN THE SKIN OF PATIENTS TREATED WITH ISOTRETINON
异维A酮治疗患者皮肤基因表达分析
  • 批准号:
    7203481
  • 财政年份:
    2005
  • 资助金额:
    $ 20.01万
  • 项目类别:
Analysis of gene expression in skin after isotretinon
异维A酸治疗后皮肤基因表达分析
  • 批准号:
    7044399
  • 财政年份:
    2003
  • 资助金额:
    $ 20.01万
  • 项目类别:
Regulation of Lipid Metabolism in Human Sebaceous Glands
人体皮脂腺脂质代谢的调节
  • 批准号:
    6624339
  • 财政年份:
    2002
  • 资助金额:
    $ 20.01万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 20.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了